Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy

Next Previous
Trial Profile

A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bintrafusp alfa (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms INTR@PID CERVICAL 017
  • Sponsors EMD Serono Research & Development Institute; Merck KGaA

Most Recent Events

  • 09 Feb 2023 This trial has been completed in France, according to European Clinical Trials Database record.
  • 03 Feb 2023 Status changed from active, no longer recruiting to completed.
  • 26 Sep 2022 Results deriving PK and AE data from studies NCT02517398, NCT02699515, NCT03840915, and NCT04246489; describing a model-informed dose modification approach for risk management of Bintrafusp alfa associated bleeding adverse events, published in the Cancer Chemotherapy and Pharmacology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top